SCHEMBL9890775

SCHEMBL9890775

CNC(=O)Cc1cc(F)ccc1-c1cccc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
SRC P12931 1/20 0.42
HTR7 P34969 1/20 0.42
LMNA P02545 1/20 0.41
DGAT2 Q96PD7 2/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
CNR2 P34972 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DCLRE1B Q9H816 1/20 0.39
CHRM3 P20309 2/20 0.39
KCNA5 P22460 1/20 0.39
KCNH2 Q12809 1/20 0.39
PTGER2 P43116 1/20 0.38
ANO1 Q5XXA6 1/20 0.38
TRPM8 Q7Z2W7 2/20 0.38
SHMT1 P34896 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396004 0.90 FFAR1 (0.46) SMN1; SMN2SRCLMNADRD2DRD4
SCHEMBL2393439 0.89 SMN1; SMN2 (0.46) SMN1; SMN2SRCHTR7LMNADRD2
SCHEMBL9890765 0.89 SMN1; SMN2 (0.43) SMN1; SMN2SRCHTR7LMNADGAT2
SCHEMBL9890787 0.87 SRC (0.41) SMN1; SMN2SRCLMNADGAT2MEN1
SCHEMBL2393668 0.87 KCNA5 (0.41) SMN1; SMN2LMNAKMT2AKCNA5SHMT1
SCHEMBL9890671 0.82 PTGDR2 (0.50) SMN1; SMN2DCLRE1BPTGER2
SCHEMBL9890773 0.82 CNR1 (0.44) LMNACHRM3KCNH2ANO1SHMT1
SCHEMBL9890774 0.81 ICMT (0.54) DCLRE1B
SCHEMBL2395717 0.80 SMN1; SMN2 (0.43) SMN1; SMN2HTR7LMNAKCNA5
SCHEMBL9890777 0.80 PSEN1 (0.46) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SMN1; SMN2 2980/4885SRC 2996/4885HTR7 672/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SMN1; SMN2 2980/4885SRC 2996/4885HTR7 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.